Tuna, Musaffe
Ju, Zhenlin
Yoshihara, Kosuke
Amos, Christopher I.
Tanyi, Janos L.
Mills, Gordon B.
Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas
Article History
Received: 24 July 2019
Revised: 28 October 2019
Accepted: 6 November 2019
First Online: 29 November 2019
Competing interests
: The authors declare that they have no competing interests with this study. GBM receives support or acts as a consultant for: AstraZeneca, ImmunoMET, Ionis, Nanostring, PDX Pharmaceuticals, Signalchem Lifesciences, Symphogen, and Tarveda.
: In this research, we used data collected by the Cancer Genome Atlas (TCGA). TCGA Ethics & Policies was originally published by the National Cancer Institute (). In addition, we used previously published and publicly available data (Supplementary Table ) and tumour samples from patients diagnosed with primary epithelial ovarian carcinoma from December 1991–December 2005 at the University of Turin, in Turin, Italy were included in this analysis, which was performed with IRB approval. All patients underwent primary cytoreductive surgery, from which research tumour specimens were obtained with informed consent.
: Partial support for this research was provided by Cancer Prevention Research Institute of Texas grant RR170048, which supports C.I.A., a CPRIT Scholar in Cancer Research.
: TCGA generated data set that was analysed during the current study is available from the following URLS:,,, and validation data set is available from the previous publications (Supplementary Table) and corresponding author on reasonable request.